Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods

N. Testoni, R. M. Lemoli, G. Martinelli, C. Carboni, S. Pelliconi, E. Ottaviani, D. Ruggeri, S. Rizzi, M. R. Motta, G. Visani, S. Tura

Research output: Contribution to journalArticle

Abstract

We evaluated 18 acute myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) patients with abnormal karyotype at diagnosis who underwent peripheral blood stem cell (PBSC) transplantation. To evaluate the presence of residual tumour cells, bone marrow (BM) samples and PBSC collections were analysed by cytogenetics and in selected cases also by fluorescence in situ hybridisation (FISH) and molecular studies. All patients were considered to be in morphologic and cytogenetic complete remission (CR) at the time of mobilisation. Seven patients showed neoplastic cells in PBSC harvest and/or BM specimen before reinfusion. Cytogenetic studies revealed contamination in apheretic collections in one patient only, while three patients had BM but not PBSC contamination. Three more patients had leukaemic cells both in the BM and PBSC. All but one (with only BM contamination) of these patients relapsed within 9 months. However, five more patients relapsed after transplantion: in four cases there was no cytogenetic sign of contamination either in PBSC or BM cells and in one case no molecular evidence was revealed either. This study suggests that, whereas the presence of leukaemic cells in autologous grafts correlates with a poor prognosis, the lack of detection of tumour cells is not always predictive of long-term disease-free survival. More importantly, PBSC collections from AML patients are not contaminated by leukaemic cells if the BM is disease-free.

Original languageEnglish
Pages (from-to)1065-1070
Number of pages6
JournalBone Marrow Transplantation
Volume22
Issue number11
Publication statusPublished - 1998

Fingerprint

Leukapheresis
Peripheral Blood Stem Cell Transplantation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Cytogenetics
Neoplasms
Bone Marrow
Bone Marrow Cells
Bone Marrow Diseases
Abnormal Karyotype
Residual Neoplasm
Fluorescence In Situ Hybridization
Disease-Free Survival
Peripheral Blood Stem Cells
Transplants

Keywords

  • AML
  • Cytogenetics
  • MDS
  • Molecular studies
  • PBSC

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients : Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. / Testoni, N.; Lemoli, R. M.; Martinelli, G.; Carboni, C.; Pelliconi, S.; Ottaviani, E.; Ruggeri, D.; Rizzi, S.; Motta, M. R.; Visani, G.; Tura, S.

In: Bone Marrow Transplantation, Vol. 22, No. 11, 1998, p. 1065-1070.

Research output: Contribution to journalArticle

Testoni, N. ; Lemoli, R. M. ; Martinelli, G. ; Carboni, C. ; Pelliconi, S. ; Ottaviani, E. ; Ruggeri, D. ; Rizzi, S. ; Motta, M. R. ; Visani, G. ; Tura, S. / Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients : Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. In: Bone Marrow Transplantation. 1998 ; Vol. 22, No. 11. pp. 1065-1070.
@article{7c33b6151ad8428e87f7b56930d59195,
title = "Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods",
abstract = "We evaluated 18 acute myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) patients with abnormal karyotype at diagnosis who underwent peripheral blood stem cell (PBSC) transplantation. To evaluate the presence of residual tumour cells, bone marrow (BM) samples and PBSC collections were analysed by cytogenetics and in selected cases also by fluorescence in situ hybridisation (FISH) and molecular studies. All patients were considered to be in morphologic and cytogenetic complete remission (CR) at the time of mobilisation. Seven patients showed neoplastic cells in PBSC harvest and/or BM specimen before reinfusion. Cytogenetic studies revealed contamination in apheretic collections in one patient only, while three patients had BM but not PBSC contamination. Three more patients had leukaemic cells both in the BM and PBSC. All but one (with only BM contamination) of these patients relapsed within 9 months. However, five more patients relapsed after transplantion: in four cases there was no cytogenetic sign of contamination either in PBSC or BM cells and in one case no molecular evidence was revealed either. This study suggests that, whereas the presence of leukaemic cells in autologous grafts correlates with a poor prognosis, the lack of detection of tumour cells is not always predictive of long-term disease-free survival. More importantly, PBSC collections from AML patients are not contaminated by leukaemic cells if the BM is disease-free.",
keywords = "AML, Cytogenetics, MDS, Molecular studies, PBSC",
author = "N. Testoni and Lemoli, {R. M.} and G. Martinelli and C. Carboni and S. Pelliconi and E. Ottaviani and D. Ruggeri and S. Rizzi and Motta, {M. R.} and G. Visani and S. Tura",
year = "1998",
language = "English",
volume = "22",
pages = "1065--1070",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients

T2 - Evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods

AU - Testoni, N.

AU - Lemoli, R. M.

AU - Martinelli, G.

AU - Carboni, C.

AU - Pelliconi, S.

AU - Ottaviani, E.

AU - Ruggeri, D.

AU - Rizzi, S.

AU - Motta, M. R.

AU - Visani, G.

AU - Tura, S.

PY - 1998

Y1 - 1998

N2 - We evaluated 18 acute myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) patients with abnormal karyotype at diagnosis who underwent peripheral blood stem cell (PBSC) transplantation. To evaluate the presence of residual tumour cells, bone marrow (BM) samples and PBSC collections were analysed by cytogenetics and in selected cases also by fluorescence in situ hybridisation (FISH) and molecular studies. All patients were considered to be in morphologic and cytogenetic complete remission (CR) at the time of mobilisation. Seven patients showed neoplastic cells in PBSC harvest and/or BM specimen before reinfusion. Cytogenetic studies revealed contamination in apheretic collections in one patient only, while three patients had BM but not PBSC contamination. Three more patients had leukaemic cells both in the BM and PBSC. All but one (with only BM contamination) of these patients relapsed within 9 months. However, five more patients relapsed after transplantion: in four cases there was no cytogenetic sign of contamination either in PBSC or BM cells and in one case no molecular evidence was revealed either. This study suggests that, whereas the presence of leukaemic cells in autologous grafts correlates with a poor prognosis, the lack of detection of tumour cells is not always predictive of long-term disease-free survival. More importantly, PBSC collections from AML patients are not contaminated by leukaemic cells if the BM is disease-free.

AB - We evaluated 18 acute myeloblastic leukaemia (AML) and myelodysplastic syndrome (MDS) patients with abnormal karyotype at diagnosis who underwent peripheral blood stem cell (PBSC) transplantation. To evaluate the presence of residual tumour cells, bone marrow (BM) samples and PBSC collections were analysed by cytogenetics and in selected cases also by fluorescence in situ hybridisation (FISH) and molecular studies. All patients were considered to be in morphologic and cytogenetic complete remission (CR) at the time of mobilisation. Seven patients showed neoplastic cells in PBSC harvest and/or BM specimen before reinfusion. Cytogenetic studies revealed contamination in apheretic collections in one patient only, while three patients had BM but not PBSC contamination. Three more patients had leukaemic cells both in the BM and PBSC. All but one (with only BM contamination) of these patients relapsed within 9 months. However, five more patients relapsed after transplantion: in four cases there was no cytogenetic sign of contamination either in PBSC or BM cells and in one case no molecular evidence was revealed either. This study suggests that, whereas the presence of leukaemic cells in autologous grafts correlates with a poor prognosis, the lack of detection of tumour cells is not always predictive of long-term disease-free survival. More importantly, PBSC collections from AML patients are not contaminated by leukaemic cells if the BM is disease-free.

KW - AML

KW - Cytogenetics

KW - MDS

KW - Molecular studies

KW - PBSC

UR - http://www.scopus.com/inward/record.url?scp=0031787875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031787875&partnerID=8YFLogxK

M3 - Article

C2 - 9877268

AN - SCOPUS:0031787875

VL - 22

SP - 1065

EP - 1070

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -